This post was originally published on this site
SILICON VALLEY — HepaTx is developing novel cell therapies for liver failure that it said will restore liver function and help patients avoid a liver transplant.
How it will make money
The Palo Alto company will sell its cell therapy product to hepatologists and/or interventional radiologists for infusion into patients with liver failure, following approval by the FDA.
Business it may disrupt
It could reduce or eliminate the need for palliative care, which addresses symptoms, but does not improve…